Skip to main content
Premium Trial:

Request an Annual Quote

DiaDexus Licenses TRAIL Proteins to Human Genome Sciences

NEW YORK, Oct.16 (GenomeWeb News) - Human Genome Sciences has acquired from DiaDexus exclusive, worldwide rights to develop and commercialize diagnostic immunohistochemical tests based on the company's TRAIL Receptor-1 and TRAIL Receptor-2 proteins

DiaDexus retains exclusive commercial rights for diagnostics based on TRAIL-R1 and TRAIL-R2 in other formats, the firm said. Terms of the deal call for DiaDexus to receive an upfront payment, clinical and commercial milestone payments, and royalties.

Human Genome Sciences originally discovered the TRAIL Receptor-1 and TRAIL Receptor-2 proteins. DiaDexus acquired diagnostic rights to them through an agreement with GlaxoSmithKline.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.